Clinical Trial Update: Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis-C (FOURward Study) [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for a short-duration combination therapy (daclatasvir, asunaprevir, BMS-791325, and sofosbuvir) in chronic hepatitis C infection; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Asunaprevir (asunaprevir)
• BMS-791325
• Daclatasvir (daclatasvir)
• Sofosbuvir (sofosbuvir)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Hepatitis C | Phase 2 | Status: COMPLETED | Results posted: 2019-05-29